Circadian changes in anticoagulant effect of heparin infused at a constant rate
- PMID: 3917812
- PMCID: PMC1417335
- DOI: 10.1136/bmj.290.6465.341
Circadian changes in anticoagulant effect of heparin infused at a constant rate
Abstract
Six patients with venous thromboembolism were treated with heparin, administered intravenously by a constant infusion pump. The initial daily dose of heparin was adjusted to keep the activated partial thromboplastin time, sampled at 0800, between 1.5 and 2.5 times the control level. Once that level was obtained, this dose was kept constant. Anticoagulation was thereafter measured, every four hours for 48 hours, by activated partial thromboplastin time, thrombin time, and coagulation factor Xa inhibition assay. The results of all three coagulation tests showed a circadian variation in the six patients. Maximum values were achieved at night and minimum values in the morning. These circadian variations were reproduced for two consecutive days. Differences between night and morning values reached almost 50% for activated partial thromboplastin time, 60% for thrombin time, and 40% for factor Xa inhibition assay. This circadian variation resulted from two rhythms, a circadian rhythm lasting 24 hours and an ultradian rhythm lasting 12 hours, which were detected by cosinor analysis for each coagulation test (p less than 0.01). A circadian rhythm was detected individually in most of the patients for each coagulation test (p less than 0.05). All patients had a nocturnal peak in activated partial thromboplastin time on both days. In four patients this peak exceeded the upper desired limit of activated partial thromboplastin time. These rhythms should be taken into account when evaluating the dosage of heparin to be administered.
Similar articles
-
[Nycthemeral change in the anticoagulant effect of heparin given at a constant rate by the intravenous route].C R Acad Sci III. 1985;300(9):385-8. C R Acad Sci III. 1985. PMID: 3922584 French.
-
Changes of activated partial thromboplastin time during constant intravenous and fixed intermittent subcutaneous administration of heparin.J Intern Med. 1989 Apr;225(4):257-60. doi: 10.1111/j.1365-2796.1989.tb00075.x. J Intern Med. 1989. PMID: 2723583
-
Heparin kinetics in venous thrombosis and pulmonary embolism.Circulation. 1976 Apr;53(4):691-5. doi: 10.1161/01.cir.53.4.691. Circulation. 1976. PMID: 1253392
-
Antithrombotic therapy in deep vein thrombosis and pulmonary embolism.Am Heart J. 1992 Apr;123(4 Pt 2):1115-22. doi: 10.1016/0002-8703(92)91070-h. Am Heart J. 1992. PMID: 1553881 Review.
-
Therapy of deep vein thrombosis.Herz. 1989 Dec;14(6):341-7. Herz. 1989. PMID: 2695442 Review.
Cited by
-
Therapeutic drug monitoring in the neonate and paediatric age group. Problems and clinical pharmacokinetic implications.Clin Pharmacokinet. 1990 Jul;19(1):1-10. doi: 10.2165/00003088-199019010-00001. Clin Pharmacokinet. 1990. PMID: 2199125 Review.
-
Susceptibility to adverse drug reactions.Br J Clin Pharmacol. 2019 Oct;85(10):2205-2212. doi: 10.1111/bcp.14015. Epub 2019 Jul 17. Br J Clin Pharmacol. 2019. PMID: 31169324 Free PMC article. Review.
-
Chronobiology in mammalian health.Mol Biol Rep. 2013 Mar;40(3):2491-501. doi: 10.1007/s11033-012-2330-4. Epub 2012 Dec 6. Mol Biol Rep. 2013. PMID: 23224435 Review.
-
Anticoagulants in venous thromboembolism.BMJ. 1988 Nov 19;297(6659):1285-8. doi: 10.1136/bmj.297.6659.1285. BMJ. 1988. PMID: 3144365 Free PMC article. Review. No abstract available.
-
Difficulties in the treatment of acute pulmonary embolism.Thorax. 1985 Oct;40(10):729-33. doi: 10.1136/thx.40.10.729. Thorax. 1985. PMID: 4060094 Free PMC article. No abstract available.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical